Pharmosa Biopharm Inc.
Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Li… Read more
Pharmosa Biopharm Inc. (6875) - Total Assets
Latest total assets as of June 2024: NT$2.22 Billion TWD
Based on the latest financial reports, Pharmosa Biopharm Inc. (6875) holds total assets worth NT$2.22 Billion TWD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pharmosa Biopharm Inc. - Total Assets Trend (2020–2023)
This chart illustrates how Pharmosa Biopharm Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Pharmosa Biopharm Inc. - Asset Composition Analysis
Current Asset Composition (December 2023)
Pharmosa Biopharm Inc.'s total assets of NT$2.22 Billion consist of 75.7% current assets and 24.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 73.0% |
| Accounts Receivable | NT$0.00 | 0.0% |
| Inventory | NT$21.91 Million | 1.6% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$91.00K | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2020–2023)
This chart illustrates how Pharmosa Biopharm Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharmosa Biopharm Inc.'s current assets represent 75.7% of total assets in 2023, a decrease from 78.7% in 2020.
- Cash Position: Cash and equivalents constituted 73.0% of total assets in 2023, down from 76.3% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 1.6% of total assets.
Pharmosa Biopharm Inc. Competitors by Total Assets
Key competitors of Pharmosa Biopharm Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Pharmosa Biopharm Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Pharmosa Biopharm Inc. generates 0.24x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Pharmosa Biopharm Inc. generates $ 0.63 in net profit.
Pharmosa Biopharm Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.29 | 18.65 | 24.65 |
| Quick Ratio | 15.97 | 18.65 | 24.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.70 Billion | NT$ 540.87 Million | NT$ 656.68 Million |
Pharmosa Biopharm Inc. - Advanced Valuation Insights
This section examines the relationship between Pharmosa Biopharm Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.67 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 66.8% |
| Total Assets | NT$1.33 Billion |
| Market Capitalization | $93.73 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pharmosa Biopharm Inc.'s assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Pharmosa Biopharm Inc.'s assets grew by 66.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Pharmosa Biopharm Inc. (2020–2023)
The table below shows the annual total assets of Pharmosa Biopharm Inc. from 2020 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | NT$1.33 Billion | +66.84% |
| 2022-12-31 | NT$799.37 Million | +36.33% |
| 2021-12-31 | NT$586.37 Million | +7.93% |
| 2020-12-31 | NT$543.27 Million | -- |